Publications
188 results found
Masouridi-Levrat S, Olavarria E, Iacobelli S, et al., 2022, Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT, BONE MARROW TRANSPLANTATION, Vol: 57, Pages: 23-30, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 2
Nicholas RS, Rhone EE, Mariottini A, et al., 2021, Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis, NEUROLOGY, Vol: 97, Pages: E890-E901, ISSN: 0028-3878
Innes AJ, Mullish BH, Ghani R, et al., 2021, Fecal microbiota transplant mitigates adverse outcomes in patients colonized with multidrug-resistant organisms undergoing allogeneic hematopoietic cell transplantation, Frontiers in Cellular and Infection Microbiology, Vol: 11, Pages: 1-8, ISSN: 2235-2988
The gut microbiome can be adversely affected by chemotherapy and antibiotics prior to hematopoietic cell transplantation (HCT).This affects graft success and increases susceptibility to multidrug-resistant organism (MDRO) colonization and infection. Weperformed an initial retrospective analysis of our use of fecal microbiota transplantation (FMT) from healthy donors as therapy forMDRO-colonized patients with hematological malignancy. FMT was performed on eight MDRO-colonized patients pre-HCT (FMT-MDROgroup), and outcomes compared with 11 MDRO colonized HCT patients from the same period. At 12 months, survival wassignificantly higher in the FMT-MDRO group (70% versus 36% p = 0.044). Post-HCT, fewer FMT-MDRO patients required intensivecare (0% versus 46%, P = 0.045) or experienced fever (0.29 versus 0.11 days, P = 0.027). Intestinal MDRO decolonization occurred in25% of FMT-MDRO patients versus 11% non-FMT MDRO patients. Despite the significant difference and statistically comparablepatient/transplant characteristics, as the sample size was small, a matched-pair analysis to non-MDRO colonized control cohorts(2:1 matching) was performed. At 12 months, the MDRO group who did not have an FMT had significantly lower survival (36.4%versus 61.9% respectively, p=0.012), and higher non relapse mortality (NRM; 60.2% versus 16.7% respectively, p=0.009) than theirpaired non-colonized cohort. There was no difference in survival (70% versus 43.4%, p=0.14) or NRM (12.5% versus 31.2%respectively, p=0.24) between the FMT-MDRO group and their paired cohort. Negative outcomes, including mortality associatedwith MDRO colonization, may be ameliorated by pre-HCT FMT, despite lack of intestinal decolonization. Further work is needed toexplore the observed benefit.
Domingo-Domenech E, Duarte RF, Boumedil A, et al., 2021, Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sezary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, BONE MARROW TRANSPLANTATION, Vol: 56, Pages: 1391-1401, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 15
Ghani R, Mullish B, Innes A, et al., 2021, Faecal microbiota transplant (FMT) prior to allogeneic haematopoietic cell transplantation (HCT) in patients colonised with multidrug-resistant organisms (MDRO) results in improved survival, ECCMID
Duarte RF, Canals C, Onida F, et al., 2010, Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, JOURNAL OF CLINICAL ONCOLOGY, Vol: 28, Pages: 4492-4499, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 132
Pavlu J, Kew AK, Taylor-Roberts B, et al., 2010, Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase, BLOOD, Vol: 115, Pages: 4018-4020, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 46
Chalandon Y, Passweg JR, Schmid C, et al., 2010, Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT, BONE MARROW TRANSPLANTATION, Vol: 45, Pages: 558-564, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 50
Basak GW, van Biezen A, Brand R, et al., 2009, Donor Lymphocyte Infusions (DLI) After Peripheral Blood Stem Cell Transplantation. A Retrospective Analysis of 357 Patients by the Chronic Leukemias Working Party EBMT, 51st Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 1283-1283, ISSN: 0006-4971
Patel B, Kirkland KE, Szydlo R, et al., 2009, Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission, HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol: 94, Pages: 1399-1406, ISSN: 0390-6078
- Author Web Link
- Cite
- Citations: 26
Guglielmi C, Iacobelli S, Apperley J, et al., 2009, DONOR LYMPHOCYTE INFUSIONS FOR CHRONIC MYELOID LEUKAEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANT: PROGNOSTIC FACTORS FOR A 'PURE' GVL EFFECT ARE DIFFERENT ACCORDING TO THE STAGE OF RELAPSE, 14th Annual Meeting of the European-Hematology-Association, Publisher: FERRATA STORTI FOUNDATION, Pages: 61-61, ISSN: 0390-6078
Ciceri F, Bonini C, Stanghellini MTL, et al., 2009, Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study, LANCET ONCOLOGY, Vol: 10, Pages: 489-500, ISSN: 1470-2045
- Author Web Link
- Cite
- Citations: 371
Malladi RK, Peniket AJ, Littlewood TJ, et al., 2009, Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML, BONE MARROW TRANSPLANTATION, Vol: 43, Pages: 709-715, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 21
Dannie E, Kew A, Nakani K, et al., 2009, Working together with patients: JACIE standards and the benefits of a patient satisfaction survey, 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, Publisher: NATURE PUBLISHING GROUP, Pages: S325-S325, ISSN: 0268-3369
Auner H, Giles C, Pavlu J, et al., 2009, Ethnicity and autologous stem cell transplantation in myeloma, 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, Publisher: NATURE PUBLISHING GROUP, Pages: S148-S148, ISSN: 0268-3369
Pavlu J, Auner H, Szydlo R, et al., 2009, Allogeneic myeloablative haematopoietic stem cell transplantation for chronic myeloid leukaemia in the imatinib era, 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, Publisher: NATURE PUBLISHING GROUP, Pages: S49-S49, ISSN: 0268-3369
Gabriel I, Sharon-Richman J, Olavarria E, et al., 2009, Efficacy, complication rates, and cost-effectiveness of chemotherapy plus granulocyte-colony-stimulating factor conditioned mobilisation of peripheral blood haematopoietic stem cells in over 150 patients with haematological malignancies, 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, Publisher: NATURE PUBLISHING GROUP, Pages: S112-S112, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 1
Duarte RF, Canals C, Onida F, et al., 2009, HLA-identical allogeneic stem cell transplantation for patients with primary cutaneous T-cell lymphoma: a retrospective analysis of the Lymphoma Working Party of the European Blood and Marrow Transplantation Group, 35th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, Publisher: NATURE PUBLISHING GROUP, Pages: S38-S38, ISSN: 0268-3369
Duarte RF, Canals C, Onida F, et al., 2009, HLA-IDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT) FOR PATIENTS WITH PRIMARY CUTANEOUS T-CELL LYMPHOMA (CTCL): A RETROSPECTIVE ANALYSIS OF THE LYMPHOMA WORKING PARTY OF THE EUROPEAN BLOOD AND MARROW TRANSPLANTATION GROUP (EBMT-LWP), Tandem Meeting on Biology of Blood and Marrow Transplantation, Publisher: ELSEVIER SCIENCE INC, Pages: 22-22, ISSN: 1083-8791
Auner HW, Giles C, Pavlu J, et al., 2009, Ethnicity and Myeloma: Experience of a Large UK Stem Cell Transplantation Center, Publisher: CIG MEDIA GROUP, LP, Pages: S84-S84, ISSN: 1557-9190
Castillo-Rama M, Grande C, Martinez-Sanchez P, et al., 2009, Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant, NEFROLOGIA, Vol: 29, Pages: 604-607, ISSN: 0211-6995
- Author Web Link
- Cite
- Citations: 4
Marin D, Milojkovic D, Olavarria E, et al., 2008, European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor, BLOOD, Vol: 112, Pages: 4437-4444, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 257
Stelljes M, van Biezen A, Slavin S, et al., 2008, The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation, BONE MARROW TRANSPLANTATION, Vol: 42, Pages: 739-742, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 9
Milojkovic D, Bua M, Apperley JF, et al., 2008, Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival, 50th Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 129-129, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 4
Stanghellini MTL, Ciceri F, Bonini C, et al., 2008, Early and Effective Immune-Recovery by Gene-Engineered Lymphocytes after Haploidentical Transplantation for Leukemia Abate Late Transplant Mortality, 50th Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 138-138, ISSN: 0006-4971
Cordonnier C, Einsele H, Rovira M, et al., 2008, Voriconazole for Secondary Prophylaxis of Invasive Fungal Infection in Allogeneic Stem Cell Transplant Recipients: Results of the VOSIFI Study. on Behalf of the VOSIFI Study Group and the Infectious Diseases Working Party of the European Bone and Marrow Transplantation Group, 50th Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 423-424, ISSN: 0006-4971
Pavlu J, Klammer M, Gabriel I, et al., 2008, Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era., 50th Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 357-357, ISSN: 0006-4971
Gabriel IH, Sharon J, Olavarria E, et al., 2008, Efficacy, Complication Rates, and Cost Effectiveness of Chemotherapy Plus Granulocyte Colony Stimulating Factor Conditioned Mobilisation of Peripheral Blood Haematopoietic Stem Cells in Over 150 Patients with Haematological Malignancies, 50th Annual Meeting of the American-Society-of-Hematology, Publisher: AMER SOC HEMATOLOGY, Pages: 829-829, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 4
Lee SJ, Kukreja M, Wang T, et al., 2008, Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia, BLOOD, Vol: 112, Pages: 3500-3507, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 100
Khorashad JS, de Lavallade H, Apperley JF, et al., 2008, Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression, JOURNAL OF CLINICAL ONCOLOGY, Vol: 26, Pages: 4806-4813, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 139
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.